TSXV:SQD.H - Post by User
Comment by
FactFinder1994on Dec 13, 2020 10:48pm
137 Views
Post# 32097417
RE:Four Pending FDA/EUA Submission/Approvals over weeks ahead
RE:Four Pending FDA/EUA Submission/Approvals over weeks ahead Each FDA EUA/approval, is worth at least $200M USD ($250M CAD) in immediate additional market cap, (before you even generate a dollar of related revenue).
That equates to an incremental 50 cents/share (CAD) on a fully diluted basis per approval.
Get all four FDA approvals, commence sales, and your approaching $3/share by the end of Fiscal 2021. (not bad, at 10 times current share price)
Follow that with aggressive growth of high margin revenues and by the end of fiscal 2022 your in the $10+ range per share.
Supportative Simple Math...
With an opportunity to do over a hundred million dollars in revenue in Fiscal 2021, at 12 to 15 times forward revenues thats equates to a $1.5B market cap, and based on 500M shares fully diluted = $3/.
Coming in at over a half billion dollars in revenue for Fiscal 2022, at 12 to 15 times forward revenues implies the market cap will be in the $7B range, and based on 525M shares fully diluted = $13/.
Coming in at over a billion dollars in revenue for Fiscal 2023, at 12 to 15 times forward revenues implies the market cap will be in the $14B range, and based on 550M shares fully diluted = $25/.
Even if you say we're optimistic by a year and it therefore takes 4 years to get to a billion dollars in revenues, and a $25 share price, I say - so what. A hundred times the current share price four years out, I'll take any day!
Remember - SQI now has the benefit of the McMaster technology collaboration which raises its already high bar. A Covid-19 Antibody test for example, that delivers GREATER than 99% accuracy is a home run.
Stay Tuned